JPMorgan holds EUR 61 target: Bayer stock slips 1.84 percent

Published on 10/19/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Crop Science raised operating profit 30.00 percent to EUR 902.00 million in the second quarter. Bayer stock costs EUR 43.64 on October 19, 2026, 1.84 percent below Xetra.

Pipeline progress meets earnings test

Finerenone filing acceptance on October 8, 2026 supports a potential new indication.
JPMorgan kept its EUR 61.00 target and Overweight rating on October 16, 2026.
Bayer stock trades at EUR 43.64 at 10:32 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.84 percent below the Xetra close of October 16, 2026.
Bayer is scheduled to publish its third-quarter results on November 3, 2026.

Fotorealistisches Bild eines Pharmaforschungslabors mit Wissenschaftlern und modernen Analysegeräten — Bayer AG (DE000BAY0017): fotorealistisches Pharmaforschungslabor mit Wissenschaftlern an modernen Analysegeräten und hellen Laborräumen, Illustration mit AI erstellt.

Bayer stock was trading at EUR 43.64 at Lang & Schwarz on October 19, 2026, down 1.84 percent from the Xetra close of October 16, 2026. t-online reported on October 16, 2026 that JPMorgan kept its Overweight rating and EUR 61.00 price target ahead of Bayer's third-quarter results.

Finerenone adds pipeline support

Bayer announced on October 8, 2026 that the U.S. Food and Drug Administration accepted its supplemental application for finerenone in chronic kidney disease without diabetes. The company said the Phase III FIND-CKD study covered more than 1,500 patients, while the treatment reduced the risk of a key cardiovascular-kidney outcome by 23 percent versus placebo, according to Bayer.

The development gives the Pharmaceuticals division a measurable pipeline catalyst, but the approval process is not complete. That distinction matters because the filing acceptance supports a possible future indication rather than current sales.

What will the third quarter show?

The chronology points to three figures. On June 25, 2026, Bayer won a 7-2 Supreme Court decision in the Durnell glyphosate case, according to finanzen.net. On August 4, 2026, Crop Science increased second-quarter adjusted operating profit by more than 30.00 percent to EUR 902.00 million. On October 16, 2026, JPMorgan kept the EUR 61.00 target and expected Bayer revenue 2.00 percent above consensus but operating profit 6.00 percent below it.

The next date is November 3, 2026, when Bayer is scheduled to publish its third-quarter report. The following listed reporting date is February 24, 2027, for the 2026 annual results, according to Depot Navigator.

Stock stays below its yearly high

Bayer's market capitalization stood at EUR 42.9 billion as of October 19, 2026. The finance data also put the 52-week range at EUR 25.78 to EUR 53.92, leaving the current Lang & Schwarz price EUR 10.28 below the high. The combination of pipeline progress, litigation exposure and a cautious earnings setup leaves the November report as the next numerical test.

Bayer was trading at EUR 43.64 at Lang & Schwarz on October 19, 2026 at 10:32 a.m. CEST, 1.84 percent below the Xetra close of October 16, 2026 at EUR 44.46. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.